Rosiglitazone, a Peroxisome Proliferator Activated Receptor Gamma (PPARγ) agonist that preserves cognition in insulin-resistant patients with early AD for 4–6 months [200] also improves cognition of Tg2576 AD mice and concomitantly increases hippocampal CRMP3/DPYSL4 expression [201]. Here, INS is linked to Alzheimer disease.